Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,shortLongTermDebt,otherCurrentAssets,longTermInvestments,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,netBorrowings,otherCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,marketState,shortName,market,exchangeDataDelayedBy,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,DRRX,67294000.0,227406000,,,-9146000,,-9146000,3168000,-5489000,-8657000,-8657000,,-528000,,,,0,2303000,10960000,7792000,-489000,,-9146000,-9146000,582505000.0,32804000.0,73463000.0,5000.0,106267000.0,23000.0,-509064000.0,1685000.0,6169000.0,-1000.0,411000.0,56073000.0,8218000.0,-1000.0,4331000.0,95356000.0,32357000.0,816000.0,20360000.0,1918000.0,1086000.0,,,,7227000.0,-1432000.0,7210000.0,-550000.0,1434000.0,163000.0,-1472000.0,-8132000.0,30000.0,36000.0,177000.0,-713000.0,671000.0,-17000.0,,,87138000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620158400,1635796800,1636142400,-0.007,-0.26,-0.18,-7.5555553,0.359,1.3594445,0.0005555153,0.00040863402,1.7518841,-0.3918841,-0.22369292,309272160,-5.2307696,3.788301,15,America/New_York,EDT,-14400000,4,-2.1582713,1.36 - 1.38,1.39,1.36,1.37,14,10,finmb_27768,REGULAR,DURECT Corporation,us_market,0,NCM,False,False,1.36,1630505909,-0.029999971,1.38,1.38,1.36,22153,NasdaqCM,DURECT Corporation,USD,537123,292016,0.15999997,0.1333333,1.2 - 2.95,-1.59,-0.53898305,1.2,2.95,1.25,,,2.95,1.2,1.3594,1.7519,537.12k,292.02k,227.41M,,182.51M,1.43%,53.01%,9.01M,14.97,4.55%,3.96%,8.59M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-284.21%,-415.33%,-24.74%,-68.09%,8.53M,0.04,-90.60%,996k,-35.22M,-37.39M,-0.0070,,88.43M,0.39,24.72M,33.65,11.60,0.36,-35.91M,-20.11M,Value,95014-4166,Healthcare,79,7,6,"DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.",Cupertino,408 777 1417,CA,8,1609372800,1625097600,3,United States,http://www.durect.com,86400,6,10260 Bubb Road,408 777 3577,Drug Manufacturers—Specialty & Generic
t-1,DRRX,75554000.0,227406000,,,-10134000,,-10134000,3531000,-6115000,-9646000,-9646000,,-525000,,,,0,2212000,11858000,8327000,-488000,,-10134000,-10134000,581632000.0,34332000.0,81723000.0,373000.0,116055000.0,23000.0,-499918000.0,1685000.0,6169000.0,-14000.0,411000.0,57545000.0,11704000.0,-14000.0,4664000.0,104811000.0,39538000.0,993000.0,18062000.0,1955000.0,2150000.0,2895000.0,,,-19082000.0,845000.0,-4106000.0,51048000.0,-2076000.0,51049000.0,36233000.0,-10709000.0,30000.0,-91000.0,-53000.0,-713000.0,659000.0,-3000.0,-1000.0,14979000.0,93107000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620158400,1635796800,1636142400,-0.007,-0.26,-0.18,-7.5555553,0.359,1.3594445,0.0005555153,0.00040863402,1.7518841,-0.3918841,-0.22369292,309272160,-5.2307696,3.788301,15,America/New_York,EDT,-14400000,4,-2.1582713,1.36 - 1.38,1.39,1.36,1.37,14,10,finmb_27768,REGULAR,DURECT Corporation,us_market,0,NCM,False,False,1.36,1630505909,-0.029999971,1.38,1.38,1.36,22153,NasdaqCM,DURECT Corporation,USD,537123,292016,0.15999997,0.1333333,1.2 - 2.95,-1.59,-0.53898305,1.2,2.95,1.25,,,2.95,1.2,1.3594,1.7519,537.12k,292.02k,227.41M,,182.51M,1.43%,53.01%,9.01M,14.97,4.55%,3.96%,8.59M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-284.21%,-415.33%,-24.74%,-68.09%,8.53M,0.04,-90.60%,996k,-35.22M,-37.39M,-0.0070,,88.43M,0.39,24.72M,33.65,11.60,0.36,-35.91M,-20.11M,Value,95014-4166,Healthcare,79,7,6,"DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.",Cupertino,408 777 1417,CA,8,1609372800,1625097600,3,United States,http://www.durect.com,86400,6,10260 Bubb Road,408 777 3577,Drug Manufacturers—Specialty & Generic
t-2,DRRX,33946000.0,227406000,,,-8813000,,4360000,3413000,-4893000,-8306000,-8306000,,-547000,,,,0,2207000,10513000,7100000,-507000,13173000.0,-8813000,4360000,529884000.0,35526000.0,40115000.0,,75641000.0,20000.0,-489784000.0,1685000.0,6169000.0,-5000.0,411000.0,21312000.0,10703000.0,-5000.0,5000000.0,63061000.0,19421000.0,940000.0,19936000.0,1864000.0,1678000.0,884000.0,14979000.0,1000000.0,-19082000.0,0.0,-4106000.0,51048000.0,-2076000.0,51049000.0,36233000.0,-10709000.0,30000.0,-91000.0,-53000.0,-713000.0,659000.0,-3000.0,-1000.0,14979000.0,52358000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620158400,1635796800,1636142400,-0.007,-0.26,-0.18,-7.5555553,0.359,1.3594445,0.0005555153,0.00040863402,1.7518841,-0.3918841,-0.22369292,309272160,-5.2307696,3.788301,15,America/New_York,EDT,-14400000,4,-2.1582713,1.36 - 1.38,1.39,1.36,1.37,14,10,finmb_27768,REGULAR,DURECT Corporation,us_market,0,NCM,False,False,1.36,1630505909,-0.029999971,1.38,1.38,1.36,22153,NasdaqCM,DURECT Corporation,USD,537123,292016,0.15999997,0.1333333,1.2 - 2.95,-1.59,-0.53898305,1.2,2.95,1.25,,,2.95,1.2,1.3594,1.7519,537.12k,292.02k,227.41M,,182.51M,1.43%,53.01%,9.01M,14.97,4.55%,3.96%,8.59M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-284.21%,-415.33%,-24.74%,-68.09%,8.53M,0.04,-90.60%,996k,-35.22M,-37.39M,-0.0070,,88.43M,0.39,24.72M,33.65,11.60,0.36,-35.91M,-20.11M,Value,95014-4166,Healthcare,79,7,6,"DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.",Cupertino,408 777 1417,CA,8,1609372800,1625097600,3,United States,http://www.durect.com,86400,6,10260 Bubb Road,408 777 3577,Drug Manufacturers—Specialty & Generic
t-3,DRRX,28299000.0,227406000,,,-9332000,,-9332000,3479000,-5391000,-8870000,-8870000,,-546000,,,,0,2683000,11553000,8074000,-462000,13173000.0,-9332000,-9332000,528804000.0,35457000.0,34698000.0,,70155000.0,20000.0,-494144000.0,1714000.0,6399000.0,18000.0,411000.0,18670000.0,9556000.0,18000.0,5478000.0,56867000.0,29943000.0,1492000.0,20679000.0,3628000.0,1106000.0,,,1000000.0,1838000.0,-909000.0,1805000.0,7103000.0,556000.0,7105000.0,224000.0,-8684000.0,80000.0,-166000.0,505000.0,-713000.0,469000.0,-33000.0,-2000.0,14979000.0,47311000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620158400,1635796800,1636142400,-0.007,-0.26,-0.18,-7.5555553,0.359,1.3594445,0.0005555153,0.00040863402,1.7518841,-0.3918841,-0.22369292,309272160,-5.2307696,3.788301,15,America/New_York,EDT,-14400000,4,-2.1582713,1.36 - 1.38,1.39,1.36,1.37,14,10,finmb_27768,REGULAR,DURECT Corporation,us_market,0,NCM,False,False,1.36,1630505909,-0.029999971,1.38,1.38,1.36,22153,NasdaqCM,DURECT Corporation,USD,537123,292016,0.15999997,0.1333333,1.2 - 2.95,-1.59,-0.53898305,1.2,2.95,1.25,,,2.95,1.2,1.3594,1.7519,537.12k,292.02k,227.41M,,182.51M,1.43%,53.01%,9.01M,14.97,4.55%,3.96%,8.59M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-284.21%,-415.33%,-24.74%,-68.09%,8.53M,0.04,-90.60%,996k,-35.22M,-37.39M,-0.0070,,88.43M,0.39,24.72M,33.65,11.60,0.36,-35.91M,-20.11M,Value,95014-4166,Healthcare,79,7,6,"DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.",Cupertino,408 777 1417,CA,8,1609372800,1625097600,3,United States,http://www.durect.com,86400,6,10260 Bubb Road,408 777 3577,Drug Manufacturers—Specialty & Generic
